Pannuti F, Gaggi R, Murari-Colalongo G, Burroni P, Fruet F, Cricca A, Camaggi C M
Oncology. 1981;38(5):307-10. doi: 10.1159/000225576.
The authors treated three groups of rats with medroxyprogesterone acetate (MAP) at different dosages (0, 2.5, 5, 10, 20, 40, 80 mg/kg) i.p. and orally for 7 days to evaluate its anabolic and its androgenic/antiandrogenic effect. 70 rats had been previously castrated and 35 were intact. The anabolic effect is evident in all groups of animals which were treated. The androgenic action predominates in castrated animals, while the antiandrogenic action predominates in intact animals. The above-mentioned actions are more marked when very high doses are used. After suggesting the possible mechanism of action of MAP, the authors point out that the anabolic effect confirms what has already been reported in clinical oncology after treatment with very high doses of MAP (1,000-2,000 mg orally or i.m. for 30 days) in different types of tumors (breast, kidney, prostate).
作者以不同剂量（0、2.5、5、10、20、40、80毫克/千克）腹腔注射和口服醋酸甲羟孕酮（MAP）对三组大鼠进行为期7天的处理，以评估其合成代谢作用以及雄激素/抗雄激素作用。70只大鼠先前已被阉割，35只为未阉割的。在所有接受处理的动物组中，合成代谢作用均很明显。雄激素作用在阉割动物中占主导，而抗雄激素作用在未阉割动物中占主导。当使用非常高的剂量时，上述作用更为显著。在提出MAP可能的作用机制后，作者指出，合成代谢作用证实了临床肿瘤学中已有报道的，在不同类型肿瘤（乳腺癌、肾癌、前列腺癌）中使用非常高剂量的MAP（口服或肌肉注射1000 - 2000毫克，持续30天）后的情况。
